BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 11793023)

  • 1. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients.
    Miyazaki Y; Glass L; Triplitt C; Matsuda M; Cusi K; Mahankali A; Mahankali S; Mandarino LJ; DeFronzo RA
    Diabetologia; 2001 Dec; 44(12):2210-9. PubMed ID: 11793023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.
    Miyazaki Y; Mahankali A; Matsuda M; Mahankali S; Hardies J; Cusi K; Mandarino LJ; DeFronzo RA
    J Clin Endocrinol Metab; 2002 Jun; 87(6):2784-91. PubMed ID: 12050251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
    Miyazaki Y; DeFronzo RA
    Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.
    Miyazaki Y; Mahankali A; Wajcberg E; Bajaj M; Mandarino LJ; DeFronzo RA
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4312-9. PubMed ID: 15356026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.
    Triplitt C; Glass L; Miyazaki Y; Wajcberg E; Gastaldelli A; De Filippis E; Cersosimo E; DeFronzo RA
    Diabetes Care; 2006 Nov; 29(11):2371-7. PubMed ID: 17065670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.
    Miyazaki Y; Mahankali A; Matsuda M; Glass L; Mahankali S; Ferrannini E; Cusi K; Mandarino LJ; DeFronzo RA
    Diabetes Care; 2001 Apr; 24(4):710-9. PubMed ID: 11315836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperlipidaemia is associated with increased insulin-mediated glucose metabolism, reduced fatty acid metabolism and normal blood pressure in transgenic mice overexpressing human apolipoprotein C1.
    Koopmans SJ; Jong MC; Que I; Dahlmans VE; Pijl H; Radder JK; Frölich M; Havekes LM
    Diabetologia; 2001 Apr; 44(4):437-43. PubMed ID: 11357474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients.
    Bajaj M; Suraamornkul S; Hardies LJ; Pratipanawatr T; DeFronzo RA
    Int J Obes Relat Metab Disord; 2004 Jun; 28(6):783-9. PubMed ID: 15024400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two days of a very low calorie diet reduces endogenous glucose production in obese type 2 diabetic patients despite the withdrawal of blood glucose-lowering therapies including insulin.
    Jazet IM; Pijl H; Frölich M; Romijn JA; Meinders AE
    Metabolism; 2005 Jun; 54(6):705-12. PubMed ID: 15931603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients.
    Miyazaki Y; He H; Mandarino LJ; DeFronzo RA
    Diabetes; 2003 Aug; 52(8):1943-50. PubMed ID: 12882909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of pioglitazone on the liver: role of adiponectin.
    Gastaldelli A; Miyazaki Y; Mahankali A; Berria R; Pettiti M; Buzzigoli E; Ferrannini E; DeFronzo RA
    Diabetes Care; 2006 Oct; 29(10):2275-81. PubMed ID: 17003306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients.
    Kumar S; Prange A; Schulze J; Lettis S; Barnett AH
    Diabet Med; 1998 Sep; 15(9):772-9. PubMed ID: 9737807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of IGF-I on FFA and glucose metabolism in control and type 2 diabetic subjects.
    Pratipanawatr T; Pratipanawatr W; Rosen C; Berria R; Bajaj M; Cusi K; Mandarino L; Kashyap S; Belfort R; DeFronzo RA
    Am J Physiol Endocrinol Metab; 2002 Jun; 282(6):E1360-8. PubMed ID: 12006367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes.
    Sironi AM; Vichi S; Gastaldelli A; Pecori N; Anichini R; Foot E; Seghieri G; Ferrannini E
    Clin Pharmacol Ther; 1997 Aug; 62(2):194-202. PubMed ID: 9284856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of oral L-carnitine supplementation on insulin sensitivity indices in response to glucose feeding in lean and overweight/obese males.
    Galloway SD; Craig TP; Cleland SJ
    Amino Acids; 2011 Jul; 41(2):507-15. PubMed ID: 20963457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl peptidase inhibitor P32/98: comparison with and combination with rosiglitazone.
    Wargent E; Stocker C; Augstein P; Heinke P; Meyer A; Hoffmann T; Subramanian A; Sennitt MV; Demuth HU; Arch JR; Cawthorne MA
    Diabetes Obes Metab; 2005 Mar; 7(2):170-81. PubMed ID: 15715890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated plasma nonesterified fatty acids are associated with deterioration of acute insulin response in IGT but not NGT.
    Stefan N; Stumvoll M; Bogardus C; Tataranni PA
    Am J Physiol Endocrinol Metab; 2003 Jun; 284(6):E1156-61. PubMed ID: 12582008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rosiglitazone treatment of patients with extreme insulin resistance and diabetes mellitus due to insulin receptor mutations has no effects on glucose and lipid metabolism.
    Vestergaard H; Lund S; Pedersen O
    J Intern Med; 2001 Nov; 250(5):406-14. PubMed ID: 11887975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes.
    Miyazaki Y; Matsuda M; DeFronzo RA
    Diabetes Care; 2002 Mar; 25(3):517-23. PubMed ID: 11874940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myocardial fatty acid oxidation in patients with impaired glucose tolerance.
    Knuuti J; Takala TO; Någren K; Sipilä H; Turpeinen AK; Uusitupa MI; Nuutila P
    Diabetologia; 2001 Feb; 44(2):184-7. PubMed ID: 11270674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.